Skip to Main Content

When physicians and scientists involved in Alzheimer’s disease gather in Boston next week for an annual conference known as CTAD — shorthand for Clinical Trials on Alzheimer’s Disease — they will wrestle with a research field in a holding pattern.

Aduhelm is available — the first treatment approved in two decades — but until there’s more information on its actual benefits and cost-effectiveness for patients, many physicians are sitting on the sidelines and waiting for additional data.


“There’s a lot of uncertainty right now,” said Ronald Petersen, a neurologist who leads the Mayo Clinic Alzheimer’s Disease Research Center. “In general, it’s good that a disease-modifying therapy is out there, but can any of these drugs that move the needle on amyloid make a clinical difference? That’s going to be important going forward.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.